SGSimon Ghaly

Simon Ghaly

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Simon Ghaly has a total of 136 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Gut Microbiota Are More Strongly Associated With Impairments in Health-Related Quality of Life Than Disease Activity in Inflammatory Bowel Disease

    by Robert D. Little, Thisun C. Jayawardana, Fan Zhang, Yashar Houshyar, Sabrina Koentgen, Nan Wu, Anuk Ellepola, Paris Tavakoli, Sophina Read, Anson Ho, et al.

    INTRODUCTION: Inflammatory bowel disease (IBD) affects health-related quality of life (HRQoL). Gut dysbiosis in IBD is common and may contribute to this observation. The aims of this study were to measure HRQoL and its association with clinical and microbial features in patients with IBD and healthy controls (HCs). METHODS: Fecal and oral samples, demographics, 36-item Short-Form Health Survey (SF-36), and 32-item Inflammatory Bowel Disease Questionnaire (IBDQ-32) surveys were collected at baseline from patients with Crohn's disease (CD), ulcerative colitis (UC) and HCs enrolled in The Australian IBD Microbiome Study. Samples underwent 16S rRNA sequencing. Associations between HRQoL variables and alpha diversity, beta diversity, and microbial taxa abundance were measured using R. RESULTS: A total of 751 participants (305 HCs, 232 CD, 214 UC) were included. HRQoL was lower in IBD participants compared with HCs using the SF-36 (physical component summary 51.6 vs 55.7, P < 0.0001 and mental component summary score 45.1 vs 52.2, P < 0.001). Despite high rates of remission, impaired IBD-HRQoL (IBDQ-32 score P = 0.015) and distinct beta diversity ( R 2 = 0.003, P = 0.019) compared with those with preserved IBD-HRQoL. Sixty-two genera were associated with at least one HRQoL measure in both patients with UC and patients with CD. The number and strength of associations between genera and HRQoL measures outweighed microbial associations with clinical and biochemical activity. DISCUSSION: Alterations in gut microbiota are associated with HRQoL outcomes in patients with IBD and HCs.


  • Open Access

    Dietary Patterns and Fibre Intake Are Associated with Disease Activity in Australian Adults with Inflammatory Bowel Disease: An Exploratory Dietary Pattern Analysis

    by Denelle Cosier, Kelly Lambert, Karen Charlton, Marijka Batterham, Robert D. Little, Nan Wu, Paris Tavakoli, Simon Ghaly, Joseph L. Pipicella, Susan Connor, et al.

    Background: Few studies have explored the relationship between habitual dietary patterns and disease activity in people with Inflammatory Bowel Disease (IBD). This cross-sectional study explored the association between dietary patterns and clinical and objective markers of inflammation in adults from the Australian IBD Microbiome Study. Methods: Dietary patterns were derived using principal component analysis (PCA) of baseline food frequency questionnaire data. Food intake was quantified using 3-day food record data. Associations between dietary intake and both clinical disease activity index (CDAI) and faecal calprotectin (FCP) were analysed. Results: Participants included 412 adults (IBD = 223, Healthy controls (HC) = 189). Both cohorts consumed poor-quality diets with inadequate servings of most food groups compared to Australian reference standards. IBD participants without FCP inflammation had significantly higher fibre intake than those with moderate FCP. In the Crohn’s Disease group, high adherence to ‘High plant diversity’ and ‘Meat eaters’ dietary patterns were associated with increased CDAI and FCP, respectively. In the combined IBD cohort, high adherence to a ‘Vegan-style’ dietary pattern was associated with increased FCP. Conclusions: There is a need for dietary modifications among Australian adults, both with and without IBD, to improve dietary fibre intake and adherence to dietary guidelines. Dietary patterns characterised by a high intake of plant foods or meat products were both positively associated with indicators of active IBD. It is possible that some participants with active IBD were modifying their diet to try to manage their disease and reduce symptoms, contributing to the association between healthier dietary patterns and active disease. Further clinical and longitudinal studies are needed to expand upon the findings. This study offers a unique contribution by utilising FCP as an objective marker of intestinal inflammation and applying dietary pattern analysis to investigate the relationship between diet and inflammatory markers.


  • Open Access

    Dietary Determinants of Metabolic and Gut Microbial Health in Patients with Inflammatory Bowel Disease

    by Gabrielle Wark, Nadeem O. Kaakoush, Dorit Samocha-Bonet, Simon Ghaly, Mark Danta

    Background: Diet has been linked to gut dysbiosis and the onset, course, and response to treatment of patients with IBD and metabolic disease. Methods: This single-centre prospective case-control study investigated the relationship between dietary intake, metabolic profile, and stool microbial composition in 57 individuals with IBD in clinical remission and 24 healthy individuals (HC). Participants’ baseline anthropometric measurements, serum metabolic parameters, lipid profiles, and oral and stool samples for microbiota testing were collected. Their dietary intake and physical activity were documented. A partially corrected correlation was performed to examine the associations between variables and p-values adjusted for multiple comparisons using the Benjamini–Hochberg equation (adj-p). Results: In participants with IBD, the intake of saturated fat correlated positively, and the intake of dietary fibre correlated negatively with anthropometric indices (saturated fat and BMI: r = 0.37, adj-p = 0.04, fibre and BMI: r = −0.45, adj-p = 0.01). Higher anthropometric indices were associated with poorer glucose control and a less favourable serum lipid profile (BMI and insulin: r = 0.48, p < 0.01, WHR and triglycerides: r = 0.57, p < 0.01). The stool microbiota of participants in the IBD group was less diverse and more similar to their oral microbiota than was observed in the HC group (Mann–Whitney U test p = 0.03). Within the IBD group, a higher intake of added sugar and processed meat and a higher serum insulin level was associated with lower stool microbial alpha diversity (processed meat intake and Shannon’s diversity: r = −0.43, adj-p = 0.02; added sugar and Shannon’s diversity: r = −0.39, adj-p = 0.03; insulin and Shannon’s diversity: r = −0.45, adj-p = 0.02). Neither the dietary intake nor stool microbial composition correlated with the risk of disease flaring. Conclusions: Our findings suggest that dietary intake is associated with the metabolic health and gut microbial composition of IBD patients.


  • Dietary Emulsifier Exposure in People With Inflammatory Bowel Disease Compared With Healthy Controls: Is There a Cause for Concern?

    by Natasha Katsoudas, Paris Tavakoli, Nan Wu, Amanda Shapiro, Steven T Leach, Astrid-Jane Williams, Ramesh Paramsothy, Simon Ghaly, Susan J Connor, Dorit Samocha-Bonet, et al.

    Emulsifiers are implicated in the pathogenesis of inflammatory bowel disease (IBD). Few studies have examined emulsifier intake in people with existing IBD. We aimed to describe the frequency of exposure to 6 selected emulsifiers in a contemporary cohort of people with IBD and compare intake with healthy controls (HCs). Baseline food records from participants in an Australian prospective cohort study examining the microbiome of IBD patients and HCs were analyzed. Exposure to inflammatory emulsifiers polysorbate-80 (P80); carboxymethylcellulose (CMC); carrageenan; xanthan gum (XG); lecithin (soy and sunflower) and mono- and diglycerides of fatty acids (MDGs) were determined by examining ingredient lists. Frequency of emulsifier exposure between groups (IBD vs HC, Crohn’s disease [CD] vs ulcerative colitis [UC], IBD children vs adults, active disease vs remission) was examined after controlling for confounders. Records from 367 participants were analyzed (n = 176 IBD, of which there were 101 CD, 75 UC, and 191 HC patients). In total, 5022 unique food items were examined, with 18% containing 1 or more emulsifier of interest. Inflammatory bowel disease participants had significantly higher total daily emulsifier exposure compared with HCs (2.7 ± 1.8 vs 2.3 ± 1.6, P = .02). In IBD participants, emulsifiers with the highest daily exposure were MDGs (1.2 ± 0.93), lecithin (0.85 ± 0.93), and XG (0.38 ± 0.42). There were no recorded exposures to P80. Inflammatory bowel disease participants were exposed to more emulsifiers than HCs. Intake of inflammatory emulsifiers were low or nonexistent, suggesting their presence in the food supply are not as common as frequently stated.


  • Open Access

    SARS‐CoV‐2 vaccination in patients with inflammatory bowel disease

    by Ralley E. Prentice, Clarissa Rentsch, Aysha H. Al‐Ani, Eva Zhang, Douglas Johnson, John Halliday, Robert Bryant, Jacob Begun, Mark G. Ward, Peter J. Lewindon, et al.

    Background The current COVID-19 pandemic, caused by Severe Acute Respiratory Syndrome-Coronavirus-2 (SARS-CoV-2), has drastically impacted societies worldwide. Vaccination against SARS-CoV-2 is expected to play a key role in the management of this pandemic. Inflammatory conditions such as inflammatory bowel disease (IBD) often require chronic immunosuppression, which can influence vaccination decisions. Aim This review article aims to describe the most commonly available SARS-CoV-2 vaccination vectors globally, assess the potential benefits and concerns of vaccination in the setting of immunosuppression and provide medical practitioners with guidance regarding SARS-CoV-2 vaccination in patients with IBD. Methods All published Phase 1/2 and/or Phase 3 and 4 studies of SARS-CoV-2 vaccinations were reviewed. IBD international society position papers, safety registry data and media releases from pharmaceutical companies as well as administrative and medicines regulatory bodies were included. General vaccine evidence and recommendations in immunosuppressed patients were reviewed for context. Society position papers regarding special populations, including immunosuppressed, pregnant and breast-feeding individuals were also evaluated. Literature was critically analysed and summarised. Results Vaccination against SARS-CoV-2 is supported in all adult, non-pregnant individuals with IBD without contraindication. There is the potential that vaccine efficacy may be reduced in those who are immunosuppressed, however medical therapies should not be withheld in order to undertake vaccination. SARS-CoV-2 vaccines are safe, but data specific to immunosuppressed patients remain limited. Conclusions SARS-CoV-2 vaccination is essential from both an individual patient and community perspective and should be encouraged in patients with IBD. Recommendations must be continually updated as real-world and trial-based evidence emerges.


  • Open Access

    Lyophilised Oral Faecal Microbiota Transplantation in Ulcerative Colitis - a Randomised Placebo-Controlled Trial

    by Craig Haifer, Sudarshan Paramosthy, Nadeem O. Kaakoush, Aiasha Saikal, Simon Ghaly, Laurence Dw Luu, Thomas J Borody, Rupert W. Leong

    Background: Colonoscopic infusion and enemas of faecal microbiota transplantation (FMT) induce remission in ulcerative colitis (UC) but whether oral FMT achieves induction and maintenance of remission in UC is unknown. Methods: A double-blind, randomised placebo-controlled trial was conducted. Following 2-weeks of amoxicillin, metronidazole and doxycycline, patients with active UC were randomised 1:1 to FMT or placebo capsules for 8-weeks. The primary outcome was steroid-free clinical remission with endoscopic remission or response. At week-8, FMT-responders were re-randomised 1:1 to continue or withdraw FMT for a further 48-weeks. Modified intention-to-treat analysis was performed and included all patients who received at least one study dose. The gastrointestinal microbiota was profiled using 16S rRNA and ITS region amplicon sequencing. This report presents the final analysis. Findings: From May 2019 to March 2020, 35 subjects were randomised (15 FMT/ 20 placebo). Recruitment was terminated early due to the SARS-COV-2 pandemic. The primary outcome was achieved in 8/15(53%) with FMT versus 3/20(15%) with placebo (difference:38·3% [95%CI: 8·6–68·0]; P =0·027; OR:5·0[95%CI: 1·8–14·1]). Ten FMT-responders entered the maintenance phase. By 56-weeks, 6/6 (100%) subjects randomised to withdraw FMT relapsed (median time to treatment escalation 24-weeks); whereas 4/4(100%) subjects on maintenance-FMT had endoscopic and histologic mucosal healing. Adverse events occurred in 10/15(67%) FMT and 18/20(85%) placebo subjects and were generally mild and self-limiting. Serious adverse events included worsening UC (2 FMT, 1 placebo) and PR bleeding (1 placebo). Antibiotics reduced pathobionts and FMT increased species richness relative to placebo (PBacteroides ovatus-like taxa in recipients. Interpretation Antibiotics followed by orally-administered FMT induces remission in subjects with active UC with corresponding microbial changes. Maintenance FMT in responders was safe, well tolerated and appeared to sustain the response achieved during induction therapy. Trial Registration: The study was registered with the Australian New Zealand Clinical Trial Registry ACTRN12619000611123. Funding: The study was supported by: St Vincent’s Clinic Foundation (2019), Gastroenterological Society of Australia (2020) and Gutsy Group (202-2021). CH is supported by a Research Entry Scholarship through the Royal Australasian College of Physicians; SP is supported by an NHMRC Investigator Grant, NOK is supported by a Scientia Fellowship from UNSW. Declaration of Interest: CH reports speaker fees and educational support from Janssen, Pfizer, Takeda, Ferring, Sandoz and Abbvie. SP has served as a consultant for Finch Therapeutics and has received speaker fees from Ferring, Janssen and Takeda. SG reports Speaker fees, educational grants or travel sponsorship from Janssen Cilag, AbbVie, Takeda, Ferring, Shire, Pfizer. Advisory board fees Pfizer and AbbVie. TJB has a pecuniary interest in the Centre for Digestive Diseases, is a medical advisor to Finch therapeutics and holds patents in FMT treatment. RWL reports personal fees from AbbVie, personal fees from Aspen, personal fees from Ferring, grants and personal fees from Hospira/ Pfizer, grants and personal fees from Janssen, grants and personal fees from Takeda, grants from Shire, grants from NHMRC, personal fees from Celgene, personal fees from Dr Falk Pharma, personal fees from Novartis, personal fees from MSD, grants from Gutsy Group, personal fees from Chiesi, personal fees from BMS, personal fees from Glutagen, outside the submitted work. All other authors have no conflicts of interest to declare. Ethical Approval: This investigator-initiated study was approved by the St Vincent’s Hospital Sydney Human Research Ethics Committee (HREC/18/SVH/219) with The University of Sydney serving as study sponsor. All patients provided written informed consent.

  • Open Access

    The Role of Diet in the Pathogenesis and Management of Inflammatory Bowel Disease: A Review

    by Gabrielle Wark, Dorit Samocha-Bonet, Simon Ghaly, Mark Danta

    Inflammatory bowel diseases, which include ulcerative colitis and Crohn’s disease, are chronic relapsing and remitting inflammatory diseases of the gastrointestinal tract that are increasing in prevalence and incidence globally. They are associated with significant morbidity, reduced quality of life to individual sufferers and are an increasing burden on society through direct and indirect costs. Current treatment strategies rely on immunosuppression, which, while effective, is associated with adverse events. Epidemiological evidence suggests that diet impacts the risk of developing IBD and modulates disease activity. Using diet as a therapeutic option is attractive to patients and clinicians alike due to its availability, low cost and few side effects. Diet may influence IBD risk and disease behaviour through several mechanisms. Firstly, some components of the diet influence microbiota structure and function with downstream effects on immune activity. Secondly, dietary components act to alter the structure and permeability of the mucosal barrier, and lastly dietary elements may have direct interactions with components of the immune response. This review will summarise the mechanisms of diet–microbial–immune system interaction, outline key studies examining associations between diet and IBD and evidence demonstrating the impact of diet on disease control. Finally, this review will outline current prescribed dietary therapies for active CD.


  • Open Access

    Myocarditis in Crohn’s disease: a case report

    by Lucy McGrath-Cadell, Nicole K Bart, Linda Lin, Simon Ghaly, Cameron J Holloway

    Background: Mobile valvular masses are often considered pathognomonic for infective endocarditis. We present a case of a young patient with mobile valvular masses in the context of myocarditis likely secondary to active ileal Crohn’s disease. Cardiac magnetic resonance (CMR) imaging was crucial in diagnosing and monitoring our patient. Case summary: A 27-year-old woman presented with pleuritic chest pain, dyspnoea, and a 3-day history of fevers. She also reported a 2-month history of intermittent visual loss in her right eye. She had a history of histologically proven ileal Crohn’s disease, diagnosed 5 months prior. She was haemodynamically unstable on presentation. Abnormalities on a transthoracic echocardiogram necessitated a transoesophageal echocardiogram. After blood cultures were sent, the patient was commenced on empirical treatment for infective endocarditis with gentamicin and flucloxacillin. Eight days after her initial presentation, all blood cultures remained negative and she was changed to empirical treatment for culture negative endocarditis with ceftriaxone and vancomycin, according to local protocol. Despite 8 days of treatment for infective endocarditis she remained febrile. A CMR was organized on Day 9 and this showed myocarditis, which changed the treatment paradigm. She responded swiftly to steroids and anti-coagulation. Discussion: In this case, echo-dense valvular lesions are not pathognomonic for infective endocarditis and a careful diagnostic process involving multi-modality imaging, including CMR, occurred to arrive at a diagnosis of myocarditis likely secondary to Crohn’s disease.


  • Australian consensus statements for the regulation, production and use of faecal microbiota transplantation in clinical practice

    by Craig Haifer, Colleen R Kelly, Sudarshan Paramsothy, David Andresen, Lito E Papanicolas, Genevieve L McKew, Thomas J Borody, Michael Kamm, Samuel P Costello, Jane M Andrews, et al.

    Objective: Faecal microbiota transplantation (FMT) has proved to be an extremely effective treatment for recurrent Clostridioides difficile infection, and there is interest in its potential application in other gastrointestinal and systemic diseases. However, the recent death and episode of septicaemia following FMT highlights the need for further appraisal and guidelines on donor evaluation, production standards, treatment facilities and acceptable clinical indications. Design: For these consensus statements, a 24-member multidisciplinary working group voted online and then convened in-person, using a modified Delphi approach to formulate and refine a series of recommendations based on best evidence and expert opinion. Invitations to participate were directed to Australian experts, with an international delegate assisting the development. The following issues regarding the use of FMT in clinical practice were addressed: donor selection and screening, clinical indications, requirements of FMT centres and future directions. Evidence was rated using the GRADE (Grading of Recommendations Assessment, Development and Evaluation) system. Results: Consensus was reached on 27 statements to provide guidance on best practice in FMT. These include: (1) minimum standards for donor screening with recommended clinical selection criteria, blood and stool testing; (2) accepted routes of administration; (3) clinical indications; (4) minimum standards for FMT production and requirements for treatment facilities acknowledging distinction between single-site centres (eg, hospital-based) and stool banks; and (5) recommendations on future research and product development. Conclusions: These FMT consensus statements provide comprehensive recommendations around the production and use of FMT in clinical practice with relevance to clinicians, researchers and policy makers.